[A20-97] Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2021
Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).
Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy
With Child-Pugh A or no liver cirrhosis: patients with viral aetiology of HCC: indication of major added benefit. Patients with non-viral aetiology of HCC: hint of considerable added benefit. With Child-Pugh B: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.